Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTX NASDAQ:LPCN NASDAQ:PMVP NASDAQ:QNTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$7.89$5.11$3.39▼$16.00$85.43M0.8137,180 shs242,138 shsLPCNLipocine$3.15-2.5%$3.25$2.68▼$6.17$17.28M1.2436,252 shs21,567 shsPMVPPMV Pharmaceuticals$1.40-1.4%$1.16$0.81▼$1.82$73.77M1.51313,187 shs154,729 shsQNTMQuantum Biopharma$23.70+1.0%$20.07$2.70▼$38.25$68.24M0.67147,380 shs131,547 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics0.00%+17.94%+59.72%+56.55%-30.67%LPCNLipocine-2.48%-8.43%+1.29%-7.62%-39.54%PMVPPMV Pharmaceuticals-1.41%-0.71%+27.27%+40.48%-15.66%QNTMQuantum Biopharma+0.98%-5.77%+23.70%+205.81%+2,369,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTXAvalo Therapeutics3.058 of 5 stars3.53.00.00.02.51.71.3LPCNLipocine2.6175 of 5 stars3.55.00.00.00.00.00.6PMVPPMV Pharmaceuticals3.5341 of 5 stars3.55.00.00.03.22.50.6QNTMQuantum BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTXAvalo Therapeutics 3.00Buy$30.00280.23% UpsideLPCNLipocine 3.00Buy$9.00185.71% UpsidePMVPPMV Pharmaceuticals 3.00Buy$5.50292.86% UpsideQNTMQuantum Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest LPCN, PMVP, QNTM, and AVTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025LPCNLipocineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.006/18/2025QNTMQuantum BiopharmaSingular ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeModerate Buy6/10/2025LPCNLipocineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.006/2/2025AVTXAvalo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$15.005/29/2025LPCNLipocineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$8.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTXAvalo Therapeutics$440K194.20N/AN/A$12.80 per share0.62LPCNLipocine$11.20M1.50N/AN/A$3.93 per share0.80PMVPPMV PharmaceuticalsN/AN/AN/AN/A$3.40 per shareN/AQNTMQuantum BiopharmaN/AN/AN/AN/A$4.54 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTXAvalo Therapeutics-$35.13MN/A0.00N/AN/AN/A111.00%58.88%8/11/2025 (Estimated)LPCNLipocine$10K-$1.02N/A∞N/AN/A-26.68%-24.77%8/6/2025 (Estimated)PMVPPMV Pharmaceuticals-$58.71M-$1.18N/AN/AN/AN/A-32.54%-29.59%8/6/2025 (Estimated)QNTMQuantum Biopharma-$14.20M-$15.98N/AN/AN/AN/A-155.20%-94.90%8/13/2025 (Estimated)Latest LPCN, PMVP, QNTM, and AVTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q1 2025LPCNLipocine-$0.41N/AN/AN/A$0.23 millionN/A8/14/2025Q2 2025PMVPPMV Pharmaceuticals-$0.39N/AN/AN/AN/AN/A8/13/2025N/AQNTMQuantum Biopharma-$0.17N/AN/AN/AN/AN/A8/11/2025Q2 2025AVTXAvalo Therapeutics-$1.43N/AN/AN/AN/AN/A5/14/2025Q1 2025QNTMQuantum Biopharma-$0.37-$1.41-$1.04-$3.53$2.09 million$2.09 million5/12/2025Q1 2025AVTXAvalo Therapeutics-$1.07-$1.25-$0.18-$1.25N/AN/A5/9/2025Q1 2025PMVPPMV Pharmaceuticals-$0.37-$0.34+$0.03-$0.34N/AN/A5/8/2025Q4 2024LPCNLipocine-$0.35-$0.35N/A-$0.35$0.35 million$0.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTXAvalo TherapeuticsN/AN/AN/AN/AN/ALPCNLipocineN/AN/AN/AN/AN/APMVPPMV PharmaceuticalsN/AN/AN/AN/AN/AQNTMQuantum BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTXAvalo TherapeuticsN/A22.6122.61LPCNLipocineN/A15.6415.64PMVPPMV PharmaceuticalsN/A16.7516.75QNTMQuantum BiopharmaN/A0.960.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTXAvalo Therapeutics87.06%LPCNLipocine9.11%PMVPPMV Pharmaceuticals90.20%QNTMQuantum Biopharma1.24%Insider OwnershipCompanyInsider OwnershipAVTXAvalo Therapeutics3.03%LPCNLipocine6.35%PMVPPMV Pharmaceuticals7.57%QNTMQuantum Biopharma8.53%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTXAvalo Therapeutics4010.83 million10.50 millionNot OptionableLPCNLipocine105.35 million5.01 millionNo DataPMVPPMV Pharmaceuticals5051.95 million48.02 millionOptionableQNTMQuantum BiopharmaN/A2.91 million2.66 millionN/ALPCN, PMVP, QNTM, and AVTX HeadlinesRecent News About These CompaniesQuantum BioPharma Licensee Unbuzzd Wellness Inc. Commences Reg D Capital Raise Campaign to Fund Growth and Possible IPOJuly 31 at 7:24 AM | globenewswire.comQuantum BioPharma Makes Strategic Investment in GameStopJuly 24, 2025 | theglobeandmail.comQuantum BioPharma purchases 2,000 shares of GameStopJuly 22, 2025 | msn.comQuantum BioPharma stock falls after GameStop share purchaseJuly 22, 2025 | investing.comQuantum Biopharma (NASDAQ:QNTM) Shares Up 3.8% - Still a Buy?July 19, 2025 | marketbeat.comQuantum BioPharma Submits its Candidate Breakthrough Patented Drug for Multiple Sclerosis for Fast-Track Program in the United Kingdom - MorningstarJuly 9, 2025 | morningstar.comMQuantum BioPharma Ltd. (QNTM) - Yahoo FinanceJuly 9, 2025 | finance.yahoo.comQuantum BioPharma Submits its Candidate Breakthrough Patented Drug for Multiple Sclerosis for Fast-Track Program in the United KingdomJuly 8, 2025 | finance.yahoo.comQNTM - Quantum BioPharma Ltd Ordinary Shares - MorningstarJuly 3, 2025 | morningstar.comMQuantum BioPharma Announces Private Placement - The Manila TimesJune 29, 2025 | manilatimes.netMQuantum BioPharma completes $600 private placement of voting sharesJune 29, 2025 | investing.comQuantum BioPharma Announces Private Placement of 12 Class A Multiple Voting Shares at a Price of $50 Per Share - Yahoo FinanceJune 29, 2025 | finance.yahoo.comQuantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering - MorningstarJune 27, 2025 | morningstar.comMQuantum BioPharma Announces Private PlacementJune 27, 2025 | globenewswire.comQuantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public OfferingJune 26, 2025 | globenewswire.comUnbuzzd Wellness Inc Ordinary Shares - Class B (Sub Voting)June 19, 2025 | morningstar.comMQuantum, CyberCatch, Kodiak at 52-Week Highs on NewsJune 18, 2025 | ca.finance.yahoo.comSingular Research Reports on Quantum BioPharma Ltd.'s Strategic Advances and Pipeline ProgressJune 18, 2025 | newsfilecorp.comNKeg, LQWD, Quantum at 52-Week Highs on NewsJune 17, 2025 | baystreet.caQuantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General HospitalJune 17, 2025 | globenewswire.comQuantum BioPharma plans special dividend tied to legal actionJune 14, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLPCN, PMVP, QNTM, and AVTX Company DescriptionsAvalo Therapeutics NASDAQ:AVTX$7.89 0.00 (0.00%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$7.90 +0.02 (+0.19%) As of 08/1/2025 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Lipocine NASDAQ:LPCN$3.15 -0.08 (-2.48%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.16 +0.00 (+0.16%) As of 08/1/2025 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.PMV Pharmaceuticals NASDAQ:PMVP$1.40 -0.02 (-1.41%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.40 0.00 (0.00%) As of 08/1/2025 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.Quantum Biopharma NASDAQ:QNTM$23.70 +0.23 (+0.98%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$23.18 -0.52 (-2.22%) As of 08/1/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
